Factors Predicting Pathological Complete Response and Survival Outcomes in Breast Cancer Patients Receiving...

Neoadjuvant chemotherapy (NACT) in breast cancer has been used for decades in patients with inflammatory, locally advanced, or inoperable breast cancer to achieve or facilitate operability and increase both local and systemic control. This retrospective analysis aims to identify risk factors for failing to achieve a pathological complete response (pCR). Additionally, the study examines factors predicting survival outcomes in breast cancer patients who received NACT. Among 224 patients who underwent NACT between 2010 and 2020, 65 patients achieved pCR. The hormone receptor (HR) status, HER2 amplification, and biological subtype of breast cancer significantly affected the patient's ability to achieve a pCR. Stage of the disease, molecular type, and histological type of breast cancer were significant predictors of overall survival in breast cancer patients who achieved pCR after NACT. Notably, early-stage disease, the luminal subtype of breast cancer, and invasive mammary carcinoma of no special type (NST) were associated with a favorable prognosis.

The online version contains supplementary material available at 10.1007/s13193-025-02218-7.